WVE Wave Life Sciences Ltd.
FY2025 10-K
Wave Life Sciences Ltd. (WVE) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Clinical-stage biotech developing RNA medicines using proprietary PRISM® platform combining multi-modal RNA-targeting modalities and chemistry innovations
- • New emphasis on obesity program WVE-007 showing positive Phase 1 data with durable fat loss and muscle preservation, supporting once or twice yearly dosing
Management Discussion & Analysis
- • Revenue $42.7M in 2025 vs $108.3M in 2024, down $65.6M YoY due to Takeda agreement termination offset by GSK revenue increase
- • Operating loss widened to $215.4M in 2025 from $110.4M in 2024; operating margin -503.8% in 2025 vs -102.0% in 2024 (calculated as loss/ revenue)
Risk Factors
- • Cybersecurity risk oversight by Audit Committee with quarterly updates on incidents and mitigation activities
- • Executive team including Data Security Officer and CFO with 50+ years combined cybersecurity experience managing risk
Get deeper insights on Wave Life Sciences Ltd.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.